Regulatory agencies like the FDA require strong safety databases for drugs that will be prescribed to millions of people, and a trial of this size provides the statistical power needed to detect both efficacy signals and uncommon adverse events
The initial data is a powerful indicator of what's possible, but the next wave of discovery will come from independent labs like yours
If considering a dose reduction for maintenance: Wait until weight has stabilized for at least 4 weeks at your current dose Reduce by one dose step (e.g., 12mg to 8mg), do not jump multiple steps Monitor weight closely for 8 weeks after the reduction If weight begins to increase, return to the previous maintenance dose The phase 3 trials specifically tested 4mg as a maintenance dose, suggesting Lilly sees viability in lower maintenance doses What happens if you stop Weight regain after discontinuing GLP-1 agonists is well documented with semaglutide and tirzepatide
Your provider should handle this, but follow up proactively
After this point, both peptide degradation and bacterial contamination risk increase beyond acceptable thresholds, even with bacteriostatic water as the diluent
